Zanubrutinib in BTKi intolerant R/R B-cell malignancies

 PDF   12/2021

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) With Relapsed/Refractory B-cell Malignancies

Rating

Rate this resource